Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Agilent TechnologiesMEX:A 89 EV-to-EBITDA is 20.05 as of Jul. 31, 2026, which is 4% below its 10-year median of 20.83. GuruFocus rates MEX:A with a GF Score™ of 89/100 and a GF Value™ of MXN2,477.74 (Fairly Valued). The stock has 2 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Agilent Technologies ranks worse than 62.18% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Agilent Technologies's enterprise value is MXN710,519 Mil.
Agilent Technologies's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was MXN35,444 Mil. Therefore, Agilent Technologies's EV-to-EBITDA for today is 20.05.
The historical rank and industry rank for Agilent Technologies's EV-to-EBITDA or its related term are showing as below:
MEX:A'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.19 Med: 20.83 Max: 35.47
Current: 20.76
During the past 13 years, the highest EV-to-EBITDA of Agilent Technologies was 35.47. The lowest was 16.19. And the median was 20.83.
MEX:A's EV-to-EBITDA is ranked worse than 62.18% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.76
vs MEX:A: 20.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Agilent Technologies's PE Ratio (TTM) for today is calculated as:
Agilent Technologies's share price for today is MXN2350.00.
Agilent Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN90.068.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Agilent Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Agilent Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's EV-to-EBITDA falls into.
Agilent Technologies's current Enterprise Value is MXN710,519 Mil.
Agilent Technologies's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN35,444 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (MEX:A) has a EV-to-EBITDA of 20.05 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Agilent Technologies. This is near median its historical median of 20.83. Over the past decade, Agilent Technologies' EV-to-EBITDA has ranged from 16.19 to 35.47. According to the industry distribution chart, Agilent Technologies ranks #74 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 62.2%.
Is Agilent Technologies' EV-to-EBITDA too high?
Agilent Technologies' current EV-to-EBITDA of 20.05 is near median its 10-year median of 20.83. Over the past 10 years, this metric has ranged from a low of 16.19 to a high of 35.47. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.76. Agilent Technologies' value of 20.05 is 27.2% above this industry median. Based on the distribution chart, Agilent Technologies ranks #74 out of 119 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Agilent Technologies has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' EV-to-EBITDA compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #74 out of 119 companies for EV-to-EBITDA. This places Agilent Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 15.76. Agilent Technologies' value of 20.05 is 27.2% above this benchmark. Historically, Agilent Technologies' own EV-to-EBITDA has ranged from 16.19 to 35.47 over the past decade. While the company's 10-year median is 20.83 vs. the industry median of 15.76, Agilent Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.76, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agilent Technologies's current EV-to-EBITDA of 20.05 is 27.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Agilent Technologies. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agilent Technologies's current EV-to-EBITDA is 20.05, which is near median its own 10-year median of 20.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (MEX:A) is currently considered Fairly Valued. The stock's GF Value™ is MXN2,477.74, compared to a current price of MXN2,350.00 — trading 5.2% below its estimated fair value. The current EV-to-EBITDA is 20.05, which is near median its 10-year median of 20.83 and 27.2% above the Medical Diagnostics & Research industry median of 15.76. Agilent Technologies' overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Agilent Technologies (MEX:A), the current EV-to-EBITDA is 20.05 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (MEX:A) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of MXN2,350.00 is trading 5.2% below its estimated GF Value™ of MXN2,477.74.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for MEX:A:
EV-to-EBITDA: 20.05 (near median its 10-year median of 20.83)
GF Value™: MXN2,477.74 vs. price of MXN2,350.00 (5.2% below fair value)
Industry Position: 27.2% above the Medical Diagnostics & Research median (#74 of 119)
No single metric tells the full story. See the MEX:A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
89GF Score
Get the complete analysis for MEX:A
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:A has been successfully added to your 
